(INFU) InfuSystems Holdings - Ratings and Ratios
Pump, Rental, Service, Oncology
INFU EPS (Earnings per Share)
INFU Revenue
Description: INFU InfuSystems Holdings
InfuSystems Holdings Inc (NYSE MKT:INFU) is a US-based company operating in the Health Care Services sub-industry. The companys stock performance is characterized by a relatively high beta of 1.814, indicating a higher volatility compared to the overall market.
The market capitalization of INFU stands at $185.21 million, with a price-to-earnings ratio of 31.54 and a forward P/E of 35.84, suggesting that investors are willing to pay a premium for the companys earnings. The return on equity (RoE) is 12.15%, indicating a moderate level of profitability.
To evaluate INFUs performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin should be closely monitored. The companys ability to generate cash flow and maintain a healthy balance sheet is also crucial. Key economic drivers for INFU include the demand for healthcare services, reimbursement rates, and competition in the industry.
From a financial perspective, the yearly Income Tax Expense is an important metric to analyze, as it can significantly impact the companys net income. A thorough examination of INFUs tax strategy and its impact on profitability is necessary to understand the companys overall financial health.
To make informed investment decisions, it is essential to assess INFUs competitive position, market trends, and growth prospects. A detailed analysis of the companys financial statements, industry reports, and market research can provide valuable insights into its potential for long-term growth and returns on investment.
INFU Stock Overview
| Market Cap in USD | 200m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2007-12-27 |
INFU Stock Ratings
| Growth Rating | 10.4% |
| Fundamental | 73.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 28.5% |
| Analyst Rating | 5.0 of 5 |
INFU Dividends
Currently no dividends paidINFU Growth Ratios
| Growth Correlation 3m | 73.1% |
| Growth Correlation 12m | -13.2% |
| Growth Correlation 5y | -78.3% |
| CAGR 5y | 11.64% |
| CAGR/Max DD 3y | 0.20 |
| CAGR/Mean DD 3y | 0.60 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | 0.18 |
| Beta | 0.523 |
| Volatility | 42.69% |
| Current Volume | 202.4k |
| Average Volume 20d | 276.2k |
| Stop Loss | 9.2 (-5.9%) |
| Signal | -1.35 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (5.07m TTM) > 0 and > 6% of Revenue (6% = 8.39m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 20.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.54% (prev 13.17%; Δ 0.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.26 (>3.0%) and CFO 26.6m > Net Income 5.07m (YES >=105%, WARN >=100%) |
| Net Debt (29.7m) to EBITDA (23.8m) ratio: 1.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (21.3m) change vs 12m ago -1.95% (target <= -2.0% for YES) |
| Gross Margin 54.55% (prev 50.05%; Δ 4.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 133.6% (prev 119.2%; Δ 14.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.31 (EBITDA TTM 23.8m / Interest Expense TTM 1.68m) >= 6 (WARN >= 3) |
Altman Z'' -1.46
| (A) 0.19 = (Total Current Assets 34.8m - Total Current Liabilities 15.9m) / Total Assets 100.8m |
| (B) -0.61 = Retained Earnings (Balance) -61.5m / Total Assets 100.8m |
| (C) 0.10 = EBIT TTM 10.6m / Avg Total Assets 104.7m |
| (D) -1.31 = Book Value of Equity -60.8m / Total Liabilities 46.3m |
| Total Rating: -1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.80
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 8.73% = 4.37 |
| 3. FCF Margin 15.06% = 3.76 |
| 4. Debt/Equity 0.77 = 2.21 |
| 5. Debt/Ebitda 1.77 = 0.44 |
| 6. ROIC - WACC (= -0.70)% = -0.88 |
| 7. RoE 9.11% = 0.76 |
| 8. Rev. Trend 94.56% = 7.09 |
| 9. EPS Trend 70.92% = 3.55 |
What is the price of INFU shares?
Over the past week, the price has changed by -3.17%, over one month by +2.62%, over three months by +58.77% and over the past year by +52.34%.
Is InfuSystems Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INFU is around 9.19 USD . This means that INFU is currently overvalued and has a potential downside of -6.03%.
Is INFU a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the INFU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.8 | 40.6% |
| Analysts Target Price | 13.8 | 40.6% |
| ValueRay Target Price | 10.1 | 3.1% |
Last update: 2025-09-18 04:36
INFU Fundamental Data Overview
CCE Cash And Equivalents = 720.0k USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 40.75
P/E Forward = 29.6736
P/S = 1.4281
P/B = 3.783
Beta = 1.829
Revenue TTM = 139.9m USD
EBIT TTM = 10.6m USD
EBITDA TTM = 23.8m USD
Long Term Debt = 26.3m USD (from longTermDebt, last quarter)
Short Term Debt = 15.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 42.2m USD (Calculated: Short Term 15.9m + Long Term 26.3m)
Net Debt = 29.7m USD (from netDebt column, last quarter)
Enterprise Value = 241.3m USD (199.8m + Debt 42.2m - CCE 720.0k)
Interest Coverage Ratio = 6.31 (Ebit TTM 10.6m / Interest Expense TTM 1.68m)
FCF Yield = 8.73% (FCF TTM 21.1m / Enterprise Value 241.3m)
FCF Margin = 15.06% (FCF TTM 21.1m / Revenue TTM 139.9m)
Net Margin = 3.63% (Net Income TTM 5.07m / Revenue TTM 139.9m)
Gross Margin = 54.55% ((Revenue TTM 139.9m - Cost of Revenue TTM 63.6m) / Revenue TTM)
Tobins Q-Ratio = -3.97 (set to none) (Enterprise Value 241.3m / Book Value Of Equity -60.8m)
Interest Expense / Debt = 1.19% (Interest Expense 503.0k / Debt 42.2m)
Taxrate = 53.65% (2.71m / 5.06m)
NOPAT = 4.90m (EBIT 10.6m * (1 - 53.65%))
Current Ratio = 2.19 (Total Current Assets 34.8m / Total Current Liabilities 15.9m)
Debt / Equity = 0.77 (Debt 42.2m / last Quarter total Stockholder Equity 54.5m)
Debt / EBITDA = 1.77 (Net Debt 29.7m / EBITDA 23.8m)
Debt / FCF = 2.00 (Debt 42.2m / FCF TTM 21.1m)
Total Stockholder Equity = 55.7m (last 4 quarters mean)
RoA = 5.03% (Net Income 5.07m, Total Assets 100.8m )
RoE = 9.11% (Net Income TTM 5.07m / Total Stockholder Equity 55.7m)
RoCE = 12.89% (Ebit 10.6m / (Equity 55.7m + L.T.Debt 26.3m))
RoIC = 5.95% (NOPAT 4.90m / Invested Capital 82.4m)
WACC = 6.65% (E(199.8m)/V(242.0m) * Re(7.94%)) + (D(42.2m)/V(242.0m) * Rd(1.19%) * (1-Tc(0.54)))
Shares Correlation 3-Years: -3.03 | Cagr: -0.07%
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈12.7m ; Y1≈8.32m ; Y5≈3.81m
Fair Price DCF = 3.66 (DCF Value 74.8m / Shares Outstanding 20.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 70.92 | EPS CAGR: 91.85% | SUE: 1.05 | # QB: 2
Revenue Correlation: 94.56 | Revenue CAGR: 10.62% | SUE: N/A | # QB: None
Additional Sources for INFU Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle